Member Info for Uncanny

Anyone in the onocology field Tony that is building their pipeline - thats what makes the 401 potential commercial deal average, good or off the radar!

Gilders, yes unfortunately dilution was the evil here, but longer term (+2 year) with right deal particulalry with 201 then I think it is bluesky here, considering the size of the prostate market and all the other applications it could be used for - scientifically very exciting times for 201 with the right readings which we should here about before EOY re:escalation. 401 is a gap plug for funding IMHO, but we may be surprised still after advanced talks are crystallised in to a deal of some sort.

Yes, but need to keep our feet planted. The highest I paid is 5.1p and lowest last week at 1.39p, with an average of 2.9p, knowing that due to the illiquidity this can turn on a sixpence. I have staged exit prices but these are double digit figures. A fair valuation now with the IP and progress would be a conservative 5p per share and a fair 401 deal should align with Aligns discounted forecast (pardon the pun) of c.10p or higher. +20p is down to 201 in IMHO, but if the rwadings this quarter are exceptionally good, any pharma worth their metal is want to sign a deal at Pl/ll All IMHO

Yes, a goldencross exists at 2.5p when the 50 dma will break the 200 dma: once broken we are in a medium term new trend, but that will take news and volume. Albeit the Dec 2017 was excellent when we roae to 7.75p, but the key for sustained SP growth is VALs commercialisation of 401 and then 201 (or both!?) to appease the market and show a sustained cashflow stream which is not via fund raising but through organic growth..... that’s coming hence why have now trippled my position from earlier this year. GLA, but the worm has turned IMHO.

C’mon 401 deal!

I think we might get news soon, I agree as large buy sizes today so maybe?!

Just need some positive news not earth shattering to break the 2.5p moving average and then we are away out of the bowl. Gues that will be 201 update or 401 deal, but could be equally from 101 and 301 update moving to CT. GLA and better volume today,

Somebody confident!

I don’t want an EGM, I just want them to get on with building the science and selling it. What a waste of money and everyone's time an EGM would be! Can someone point to where a negative RNS was announced please? I can only see positives.

What would that do?????

Buying!

Didn't the buy order by Hsrdman note say buy at the placement level of 1.5p

Just getting my bonus soon so if the price can stay here until Dec then I’m loading up again. The science works! The negotiators on the deal are not VAL but pro-business people. The compounds are shrouded in LT patents. The SP resembles nothing to the value here - just impatient mkts and stop losses getting triggered by margined investors and traders on long term settlements that need to close. Buy and hold is my strategy plus forget the noise!

Tony you are quite mistaken in that 22nd in Edin is just a presentation - if news arrives or not makes no difference, but welcome of course This is a LT investment not a fast buck since developments in 2017. Things on track here and the SP is so seriously detracted from developments. Just ride it out guys, trolls and scaremongers trying to frighten PI’s The problem with VAL at this juncture is lack of instituional buyers because the mkt cap is off the radar, but with 401 jv and 201 readout we are in to a different arena, so easy pickings for the shorters and trolls. All IMHO.

SCIENTIFIC MEETINGS 6(th) CPC Symposium on Peptide Therapeutics Conference, held in Hangzhou, China on 17- 19 October 2018 Dr George Morris, Chief Operating Officer at ValiRx PLC, was invited and recently presented a paper at the 6(th) CPC Symposium on Peptide Therapeutics in Hangzhou, China. The Symposium traditionally brings together scientific leaders in peptide-based therapeutics from across the biopharmaceutical industries and academia and it provides a forum for scientific discussion on recent developments in the field of peptide therapeutics. Dr Morris presented a paper entitled "A decapeptide (VAL201 - Pro-Pro-Pro-His-Pro-His-Ala-Arg-Ile-Lys) modulating hormone induced proliferative indications". The paper examined preliminary results and data from the Phase I/II Clinical Study of the Company's therapeutic peptide (VAL201) and its targeting of the interaction between steroid hormone receptors and c-Src to inhibit cell proliferation activity, without blocking desirable receptor-dependent transcriptional activity and thereby eliminating most side effects associated with more general Src kinase inhibitors or with hormone deprivation therapies. House of Lords' Life Sciences Industrial Strategy Reception on Monday 29(th) October 2018 Dr Satu Vainikka, CEO was invited by Viscount Matt Ridley DL on behalf of Professor Sir John Bell GBE to a Life Sciences reception last week at the House of Lords, which involved a group debate and feedback session. The industry experts participating in the meeting discussed the issues relating to the UK's Life Sciences Industrial Strategy, both as they pertain currently and in the future. The debate was both wide ranging and informative. 5(th) Annual Clinical Operations in Oncology Europe Conference, held in Munich, Germany on 14-15 November 2018 Dr Morris will be attending and speaking next week at the Annual Clinical Operations in Oncology Europe Conference, in Munich, Germany. His speech, entitled "The bird's eye view: Defining strategy to maintain vendor oversight in oncology clinical trials", will discuss various aspects pertaining to the running and management of the clinical trial process within GCP and regulatory guidelines. INVESTOR MEETING Shares and AJ Bell Investor Evening in Edinburgh, held at the Radisson Blu Hotel at 18:00 on Thursday, 22 November 2018 Dr Morris and colleagues, Tarquin Edwards, Head of Comms/IR and Kumar Nawani, Head of Operations, will attend the event, with Dr Morris making a presentation about the Company to existing and potential new investors. He will discuss both the Company's current progress as far as its clinical and pre-clinical drug development programmes are concerned and will outline the company's business plans for the rest of 2018 and into the new year

Whilst we are in the dark, it easy for the human instinct to take over and fear the worst. Lets see what happens as all the news is positive so far - developments, patents, talks, compound updates and the recent PR / broker notes. Not one negative, in fact I joked with VAL in an email that perhaps they should announce bad bews as the SP might go up..... they also said the same! Funding is there until the end of the first qtr 2019 and whose to say we won’t get an RNS on 401 deal within the next 5 months.... my guess it is closer than we think BWTFIK. 201 readout is to come in the next 6 weeks according to the Hardman diary and that could signal a repeat of last Dec, fingers crossed.

I bought 750k yesterday and didn’t make a dent!

Agree Harley and hopefully that will be the catalyst that builds the share price rather than the drifting at present.

The 201 readout is scheduled for this quarter - maybe that is the bombshell (positive) that GM might announce to coincide with Edinburgh and Munich?

Valju Not sure. More value would be assigned to individual dela although a 401 and 201 joint deal could be geasable. I would have thought VAL have a good idea of how the 201 escalation has worked - “it bloody works” according to GM! I think we are at crossroads and frustrating for investors where the BoD have the comfort of full knowledge. 401 warrants a Plll, 201 is our nearest holy grail and 101 and 301 waotong for CT. The cash burn I would have thought has fallen to at least 25% and if a deal is being talked on for 201 at Pl/ll then that will drop to c.50% by 2nd qtr 2019 as the CT has finished. I think 201 personally will go straight to commercial talks if the results match expectations at this phase.